Analysis of the CΥP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population

被引:107
作者
Tateishi, T
Chida, M
Ariyoshi, N
Mizorogi, Y
Kamataki, T
Kobayashi, S
机构
[1] St Marianna Univ, Sch Med, Dept Pharmacol, Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
[2] Hokkaido Univ, Grad Sch Pharmaceut Sci, Div Pharmacobiodynam, Lab Drug Metab, Sapporo, Hokkaido 060, Japan
[3] Tokokai Daiichi Hosp, Clin Pharmacol Ctr, Tokyo, Japan
关键词
D O I
10.1016/S0009-9236(99)70077-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To analyze the CYP2D6 allele frequencies in a Japanese population and to evaluate the effects of CYP2D6 variants on in vivo CYP2D6 activity as measured by the dextromethorphan metabolic ratio (MR). Methods: Ninety-eight unrelated, healthy Japanese men were phenotyped with dextromethorphan and genotyped by the polymerase chain reaction amplification method for 7 CYP2D6 alleles. Results:The CYP2D6*1, CYP2D6*10 CYP2D6*2 CYP2D6*5, CYP2D6*4, and CYP2D6*21 allele frequencies in our Japanese subjects were 0.423, 0.408, 0.092, 0.061, 0.020, and 0.010, respectively. Thirty-three subjects (33.7%) were heterozygous for *10/*1, and 18 (18.4%) and 17 (17.3%) subjects were homozygous for *1 and *10 respectively. Subjects who were homozygous for *10 showed the highest dextromethorphan MR among these 3 genotypes. Eighteen subjects (18.3%) were heterozygous for *2 but their dextromethorphan MR values were not greater than the MR values of subjects who were homozygous for *1. One subject was a poor metabolizer phenotypically, and he was homozygous for *5. Conclusions The CYP2D6 allele frequencies in our Japanese subjects differed from those determined in previous studies of white subjects or mainland Chinese subjects. Individuals homozygous for *10 who have relatively low in vivo CYP2D6 activity represent almost 20% of the Japanese population. In addition, we did not identify any subjects with amplified *2 among our 98 Japanese men.
引用
收藏
页码:570 / 575
页数:6
相关论文
共 24 条
[21]   POLYMORPHIC DEXTROMETHORPHAN METABOLISM - CO-SEGREGATION OF OXIDATIVE O-DEMETHYLATION WITH DEBRISOQUIN HYDROXYLATION [J].
SCHMID, B ;
BIRCHER, J ;
PREISIG, R ;
KUPFER, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (06) :618-624
[22]   MOLECULAR-BASIS OF GENETIC-VARIATION IN DEBRISOQUIN HYDROXYLATION IN CHINESE SUBJECTS - POLYMORPHISM IN RFLP AND DNA-SEQUENCE OF CYP2D6 [J].
WANG, SL ;
HUANG, JD ;
LAI, MD ;
LIU, BH ;
LAI, ML .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (04) :410-418
[23]  
WERNER K, 1991, TRENDS PHARMACOL SCI, V12, P102
[24]   A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype [J].
Yokoi, T ;
Kosaka, Y ;
Chida, M ;
Chiba, K ;
Nakamura, H ;
Ishizaki, T ;
Kinoshita, M ;
Sato, K ;
Gonzalez, FJ ;
Kamataki, T .
PHARMACOGENETICS, 1996, 6 (05) :395-401